Rahul Banerjee: All I care about in myeloma is VGPR report

Rahul Banerjee, Assistant Professor at UW Medicine, shared Rafael Fonseca’s post on X, adding:               .

“This! All I care about in myeloma is ≥VGPR vs <VGPR in terms of determining next steps diagnostically and therapeutically.

Next step is MRD (Minimal Residual Disease) assessment, not a 24-hour urine to confirm <100mg in unless they’re on trial in which it’s inevitable for the time being.”

Quoting Rafael Fonseca’s post:

“Reporting in trials response categories (PR vs VGPR vs CR vs sCR) and later showing MRD seems a wasteful redundancy.

Is like rounding and spending time discussing a plain chest X-ray, only to move on and discuss the chest CT.”

Source: Rahul Banerjee/X and Rafael Fonseca/X

Dr. Rafael Fonseca, M.D., is a hematologist at Mayo Clinic, specializing  in multiple myeloma and related conditions.. Dr. Fonseca’s expertise extends to diagnosing and treating plasma cell disorders, leading clinical trials that have advanced myeloma treatment.